RIBOONCOSTAR
LIVE

Serial Number

79386745

Owner

Suzhou Ribo Life Science Co., Ltd.

Attorney

Zhi Dong

Filing Date

Nov 10, 2023

Add to watchlist:

No watchlists yet
View on USPTO

RIBOONCOSTAR Trademark

Serial Number: 79386745 • Registration: 7726189

RIBOONCOSTAR is a trademark filed by Suzhou Ribo Life Science Co., Ltd. on November 10, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Suzhou Ribo Life Science Co., Ltd. (10 trademarks)

168 Yuanfeng Road,

Entity Type: 16

Trademark Details

Filing Date

November 10, 2023

Registration Date

March 18, 2025

Published for Opposition

January 28, 2025

Goods & Services

Medicines for humans for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; crude drugs being pharmaceutical preparations for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; pharmaceutical preparations for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; chemico-pharmaceutical preparations for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; biological preparations for medical purposes for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; chemical preparations for pharmaceutical purposes for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; chemical preparations for medical purposes for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; drugs for medical purposes, namely, pharmaceutical preparations for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; diagnostic preparations for medical purposes; potassium salts for medical purposes; sodium salts for medical purposes; pharmaceuticals for the treatment of cancer; anti-cancer preparations; biopharmaceuticals for the treatment of cancer; pharmaceutical preparations for the prevention and treatment of cancer; tumor suppressing agents; pharmaceutical preparations for suppressing tumors; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for the central nervous system; pharmaceuticals for the treatment of infectious diseases; pharmaceutical preparations for the treatment of hypercholesteremia; pharmaceutical preparations for the treatment of hyperlipidemia; pharmaceutical preparations for treating diabetes; pharmaceutical agents affecting metabolism; anticoagulants; cardiovascular pharmaceuticals; pharmaceutical preparations for ocular or intraocular surgery; dietetic food and beverages adapted for medical use; depuratives for the body; medicines for veterinary purposes, namely, veterinary preparations for the treatment and diagnosis of gastrointestinal diseases, cardiovascular diseases, metabolic diseases, and liver diseases; pesticides; dressings, medical; composite materials for dental purposes; diapers for pets

Technological research in the field of pharmaceutical manufacturing processes and pharmaceutical studies; development of pharmaceutical preparations and medicines; pharmaceutical product evaluation; pharmaceutical research and development services; research in the field of pharmaceuticals; scientific research; chemical research and analysis; development and testing of chemical production methods; biochemical research and analysis; scientific research in the nature of conducting clinical trials for others; medical research; testing of pharmaceuticals; industrial design

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Oct 18, 2025 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Sep 26, 2025 FICS
FINAL DISPOSITION PROCESSED
Sep 26, 2025 FIMP
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Jun 20, 2025 OPNX
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jun 18, 2025 FICR
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jun 3, 2025 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Jun 3, 2025 OPNR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Mar 18, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Mar 18, 2025 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 28, 2025 NPUB
PUBLISHED FOR OPPOSITION
Jan 28, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 22, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 2, 2025 CNSA
EXAMINER'S AMENDMENT ENTERED
Jan 2, 2025 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jan 2, 2025 GNEN
EXAMINERS AMENDMENT E-MAILED
Jan 2, 2025 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jan 2, 2025 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 30, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 30, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 30, 2024 TROA
REFUSAL PROCESSED BY IB
Jul 28, 2024 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jul 10, 2024 RFCS
REFUSAL PROCESSED BY MPU
Jul 10, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jun 21, 2024 RFCR
NON-FINAL ACTION WRITTEN
Jun 20, 2024 CNRT
ASSIGNED TO EXAMINER
Jun 18, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Jan 9, 2024 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 5, 2024 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jan 4, 2024 REPR